RU2764547C2 - Конъюгаты аналогов эксенатида с замедленным высвобождением - Google Patents

Конъюгаты аналогов эксенатида с замедленным высвобождением Download PDF

Info

Publication number
RU2764547C2
RU2764547C2 RU2018136200A RU2018136200A RU2764547C2 RU 2764547 C2 RU2764547 C2 RU 2764547C2 RU 2018136200 A RU2018136200 A RU 2018136200A RU 2018136200 A RU2018136200 A RU 2018136200A RU 2764547 C2 RU2764547 C2 RU 2764547C2
Authority
RU
Russia
Prior art keywords
optionally substituted
alkyl
peptide
exenatide
hydrogel
Prior art date
Application number
RU2018136200A
Other languages
English (en)
Russian (ru)
Other versions
RU2018136200A (ru
RU2018136200A3 (https=
Inventor
Эрик Л. ШНАЙДЕР
Брайан ХЁРН
Джеффри К. ХЕНИЗ
Гари В. ЭШЛИ
Даниэл В. САНТИ
Original Assignee
ПРОЛИНКС ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПРОЛИНКС ЭлЭлСи filed Critical ПРОЛИНКС ЭлЭлСи
Publication of RU2018136200A publication Critical patent/RU2018136200A/ru
Publication of RU2018136200A3 publication Critical patent/RU2018136200A3/ru
Application granted granted Critical
Publication of RU2764547C2 publication Critical patent/RU2764547C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2018136200A 2016-03-16 2017-03-16 Конъюгаты аналогов эксенатида с замедленным высвобождением RU2764547C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662309330P 2016-03-16 2016-03-16
US62/309,330 2016-03-16
US201662416058P 2016-11-01 2016-11-01
US62/416,058 2016-11-01
PCT/US2017/022791 WO2017161174A1 (en) 2016-03-16 2017-03-16 Extended release conjugates of exenatide analogs

Publications (3)

Publication Number Publication Date
RU2018136200A RU2018136200A (ru) 2020-04-16
RU2018136200A3 RU2018136200A3 (https=) 2020-12-25
RU2764547C2 true RU2764547C2 (ru) 2022-01-18

Family

ID=59852218

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018136200A RU2764547C2 (ru) 2016-03-16 2017-03-16 Конъюгаты аналогов эксенатида с замедленным высвобождением

Country Status (13)

Country Link
US (1) US20200164083A1 (https=)
EP (2) EP3429608A4 (https=)
JP (1) JP7017248B2 (https=)
KR (1) KR20180129825A (https=)
CN (1) CN109414469A (https=)
AU (2) AU2017234680A1 (https=)
BR (1) BR112018068639A2 (https=)
CA (1) CA3016814A1 (https=)
MX (1) MX2018011149A (https=)
RU (1) RU2764547C2 (https=)
SG (1) SG11201807832VA (https=)
WO (1) WO2017161174A1 (https=)
ZA (2) ZA201805953B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745456B2 (en) * 2015-04-01 2020-08-18 The Scripps Research Institute Methods and compositions related to GPCR agonist polypeptides
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CN119970617A (zh) 2019-04-05 2025-05-13 普罗林科斯有限责任公司 改良偶联接头
MX2022001528A (es) * 2019-08-07 2022-03-11 Prolynx Llc Esterilizacion con vapor de hidrogeles reticulados por enlazadores beta-eliminativos.
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
AU2022205377A1 (en) 2021-01-08 2023-07-20 Cellanome, Inc. Devices and methods for analyzing biological samples
US12576400B2 (en) 2021-01-08 2026-03-17 Cellanome, Inc. Methods for incubating and analyzing a cell in a compartment of a fluidic device
WO2025128916A1 (en) * 2023-12-13 2025-06-19 Cellanome, Inc. Devices and methods for analyzing biological samples
KR102716759B1 (ko) 2023-12-20 2024-10-15 (주)인벤티지랩 엑세나타이드를 포함하는 서방형 주사제 조성물 및 이의 제조 방법
WO2026020143A1 (en) * 2024-07-19 2026-01-22 Prolynx Llc Extended-release conjugates of lipidated peptides, and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
US20110268807A1 (en) * 2008-08-04 2011-11-03 James Su Biodegradable Microspheres and Methods of Use Thereof
US20130116407A1 (en) * 2010-05-05 2013-05-09 Gary Ashley Controlled release from macromolecular conjugates
US20130123487A1 (en) * 2010-05-05 2013-05-16 Prolynx Llc Controlled release from solid supports
RU2573995C2 (ru) * 2009-11-13 2016-01-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, содержащая агонист гпп-1 и метионин

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278589T3 (es) * 1999-01-14 2007-08-16 Amylin Pharmaceuticals, Inc. Excendinas destinadas a la inhibicion de glucagon.
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
CN100540565C (zh) * 2005-01-14 2009-09-16 无锡宏创医药科技有限公司 修饰的Exendins及其应用
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN101125207B (zh) * 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
WO2011156407A2 (en) * 2010-06-09 2011-12-15 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists to treat pancre-atitis
CA2848142C (en) 2011-09-07 2021-05-18 Prolynx Llc Hydrogels with biodegradable crosslinking
US20140256626A1 (en) * 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
US20110268807A1 (en) * 2008-08-04 2011-11-03 James Su Biodegradable Microspheres and Methods of Use Thereof
RU2573995C2 (ru) * 2009-11-13 2016-01-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, содержащая агонист гпп-1 и метионин
US20130116407A1 (en) * 2010-05-05 2013-05-09 Gary Ashley Controlled release from macromolecular conjugates
US20130123487A1 (en) * 2010-05-05 2013-05-16 Prolynx Llc Controlled release from solid supports
US8946405B2 (en) * 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports

Also Published As

Publication number Publication date
CN109414469A (zh) 2019-03-01
ZA201905787B (en) 2021-03-31
AU2021232810A1 (en) 2021-10-14
AU2017234680A1 (en) 2018-10-11
AU2017234680A2 (en) 2018-12-13
MX2018011149A (es) 2019-05-30
CA3016814A1 (en) 2017-09-21
EP3429608A1 (en) 2019-01-23
EP3429608A4 (en) 2019-12-11
BR112018068639A2 (pt) 2019-07-30
WO2017161174A1 (en) 2017-09-21
RU2018136200A (ru) 2020-04-16
EP3922269A1 (en) 2021-12-15
JP7017248B2 (ja) 2022-02-08
RU2018136200A3 (https=) 2020-12-25
US20200164083A1 (en) 2020-05-28
ZA201805953B (en) 2019-11-27
SG11201807832VA (en) 2018-10-30
KR20180129825A (ko) 2018-12-05
JP2019511497A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
RU2764547C2 (ru) Конъюгаты аналогов эксенатида с замедленным высвобождением
JP6931033B2 (ja) インスリン受容体部分アゴニスト
KR20160075665A (ko) 소마토스타틴 및 그 유사체의 컨쥬게이트
HK40064590A (en) Extended release conjugates of exenatide analogs
NZ786229A (en) Extended release conjugates of exenatide analogs
US20240277816A1 (en) Polypeptide conjugate and application thereof in preparation of drug for treating diseases related to glucose metabolism
BR122024000898B1 (pt) Composto, composição, e, uso do composto
EA041034B1 (ru) Частичные агонисты инсулинового рецептора
BR122024000903B1 (pt) Composto, composição, e, uso do composto